You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
輝瑞料全年新冠疫苗銷售額360億美元 勝預期
阿思達克 11-03 08:53
輝瑞(PFE.US)第三季盈利增長按年4.55倍至81.46億美元,收入增長1.3倍至240.94億美元。當中新冠疫苗在上季的收入貢獻達到130億美元,預計將佔全年總收入的44%。 集團預計疫苗今年的銷售額將達到360億美元,而到明年銷售額爲290億美元,優於市場預期。集團表示,目前正在尋求與各國簽署更多疫苗協議,有可能會進一步推高明年的銷售額,公司目前有能力在明年生產40億劑疫苗,並會在明年向中低收入國家提供至少10億劑疫苗。 輝瑞首席科學官Mikael Dolsten 表示,已經計劃對第四劑疫苗進行臨牀測試,可能會爲每年接種一針疫苗產生支持性數據,公司或會在明年流感季節之前申請每年接種一針的申請。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account